Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]
Pfizer said that a phase 3 clinical trial of XELJANZ (tofacitinib) in adults with active ankylosing spondylitis (AS) has met its primary endpoint. The late-stage study’s primary endpoint is assessment in SpondyloArthritis International Society (ASAS) 20 response, compared to placebo at week 16. This was after the percentage of patients achieving an ASAS20 response was […]
The US Federal Trade Commission (FTC) has granted conditional approval for Dutch pharma company Mylan’s acquisition of Upjohn, the off-patent branded and generic established medicines business of Pfizer. The deal was announced in July 2019 with an objective to create a new global pharma company through the merger of Mylan and Upjohn, which will be […]
Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage trial is being held by the US pharma giant with the German Breast Group (GBG) sponsoring it. The primary endpoint of the PENELOPE-B clinical trial is improved invasive disease-free survival […]
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]
Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter’s investigational antiviral remdesivir for the treatment of Covid-19. Under the deal terms, Pfizer will offer contract manufacturing services at its McPherson, Kansas facility for the manufacture and supply of remdesivir. Earlier this year, Pfizer came out with a five-point plan, […]
Pfizer and BioNTech have signed an agreement with the Canadian government to supply their mRNA-based BNT162 vaccine candidate against SARS-CoV2, depending on clinical success and approval from Health Canada. Financial details of the deal were not revealed. However, the terms in the deal were based on the timing of delivery and the volume of the […]
Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine candidate. Recently, the two pharma companies were granted the fast track designation from the US Food and Drug Administration (FDA) for BNT162b1 and BNT162b1 vaccines, which are two of the […]
Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track designation from the USFood and Drug Administration (FDA). The two vaccine candidates are part of the four investigational vaccine candidates that are being jointly developed by the companies under their […]
US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines. The company’s 20vPnC, which is a 20-valent pneumococcal polysaccharide conjugate vaccine candidate, will be evaluated in two phase 3 trials NCT04382326 and NCT04379713. Both the late-stage trials will evaluate a four-dose series in infants starting at the […]